5 'Key Pipeline Catalysts' To Watch At Eli Lilly
In a report published Monday, Tigress Financial Partners analyst Philip Van Deusen maintained a Buy rating on Eli Lilly and Company (NYSE: LLY).
"LLY is successfully transitioning its drug portfolio to mitigate the effects of generic competition against its blockbuster drugs Cymblata and Evista. We expect this transition to accelerate in 2015 as LLY makes progress on what is in our opinion the most promising diabetes and oncology drug pipelines of any major pharma company," Van Deusen wrote.
In the report, Tigress Financial Partners highlighted key pipeline catalysts for Eli Lilly for 2015. On the oncological front, the two catalyst cited by Van Deusen were (1) "the regulatory submission of Baricitinib, which is being developed jointly with Incyte (INCY-US, Not rated), and is targeting patients with active rheumatoid arthritis. (2) "…regulatory submissions of Ramucirumab, for both second-line non- small-cell lung cancer and second-line metastic colorectal cancer. In the diabetes pipeline, the catalyst highlighted by the analyst were (3) "the regulatory submission of Empagliflozin for type 2 diabetes in Europe" (4) "regulatory action on Empagliflozin in the US" and (5) Dulaglutide for type 2 in Japan."
Latest Ratings for LLY
|Sep 2016||Goldman Sachs||Upgrades||Neutral||Buy|
|Sep 2016||JP Morgan||Maintains||Overweight|
|Sep 2016||JP Morgan||Upgrades||Neutral||Overweight|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.